<p>UCB 宣佈了來自第 3 期 BE BOLD 試驗第 16 周的新結果，顯示 bimekizumab 在活躍性銀屑病關節炎成人患者中提供了優於 risankizumab 的關節結果。</p>
<p>在 2026 年倫敦 EULAR 年會上發佈的數據標誌着首個獲批生物製劑在銀屑病關節炎的頭對頭研究中顯示出統計學上顯著的關節結果優越性。</p>
<p>主要終點達成，接受 bimekizumab 治療的患者中有 49.1% 在第 16 周達到了 ACR50，而接受 risankizumab 治療的患者中為 38.4%。</p>
<p>在次要終點上也觀察到了改善，儘管這些結果在預先指定的測試層級中未達到統計學顯著性。bimekizumab 在所有次要指標上的反應均高於數值。</p>
<p>格拉斯哥大學的 Iain McInnes 教授表示：“提供高水平的臨牀反應對銀屑病關節炎患者至關重要。在臨牀試驗中達到 ACR50 水平的反應表明關節改善，與疾病活動性、炎症控制及隨之而來的生活質量改善密切相關。</p>
<p>“新的 BE BOLD 數據顯示，bimekizumab 在直接頭對頭試驗設計中在第 16 周的 ACR50 上優於 risankizumab，可以支持臨牀醫生在治療這種慢性炎症性疾病時做出早期知情決策。”</p>
<p>UCB 的執行副總裁 Emmanuel Caeymaex 表示：“我們很自豪地宣佈結果，證明 bimekizumab 在改善關節結果方面優於 risankizumab，提供了重要證據，可以為銀屑病關節炎的治療格局提供指導。</p>
<p>“頭對頭試驗是比較臨牀研究中最嚴格的方法。BE BOLD 反映了 UCB 對科學卓越的承諾，通過生成高質量的證據，支持改善銀屑病患者的護理。”</p>
<p>早期的關節改善在第 4 周就已顯現，接受 bimekizumab 治療的患者中有 19.9% 達到了 ACR50，而接受 risankizumab 治療的患者中為 7.2%。在第 16 周，接受 bimekizumab 的患者中有 53.4% 實現了完全皮膚清除（PASI100），而接受 risankizumab 的患者中為 46.6%。</p>
<p>未發現新的安全信號。bimekizumab 的念珠菌感染髮生率較高，但均為輕度或中度，且沒有病例導致停藥。治療出現的不良事件發生率在治療組之間相當，停藥率低且相同。</p>

UCBJY

標普生物技術 3 倍做多 - Direxion

<p>UCB 宣佈其 3 期 BE BOLD 試驗的積極結果，顯示 bimekizumab 在治療活動性銀屑病關節炎方面優於 risankizumab。在第 16 周，49.1% 的 bimekizumab 患者達到了 ACR50，而 risankizumab 的比例為 38.4%。早期改善在第 4 周就已顯現。雖然沒有報告新的安全隱患，但 bimekizumab 患者中輕度至中度的念珠菌感染更為常見</p>

<p>UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered superior joint outcomes to risankizumab in adults with active psoriatic arthritis.</p>
<div class="lb-trans"><p>UCB 宣佈了來自第 3 期 BE BOLD 試驗第 16 周的新結果，顯示 bimekizumab 在活躍性銀屑病關節炎成人患者中提供了優於 risankizumab 的關節結果。</p>
</div><p>The data, presented at the 2026 EULAR Annual Meeting in London, mark the first time an approved biologic has demonstrated statistically significant superiority in joint outcomes in a head‑to‑head psoriatic arthritis study.</p>
<div class="lb-trans"><p>在 2026 年倫敦 EULAR 年會上發佈的數據標誌着首個獲批生物製劑在銀屑病關節炎的頭對頭研究中顯示出統計學上顯著的關節結果優越性。</p>
</div><p>The primary endpoint was met, with 49.1% of patients receiving bimekizumab achieving ACR50 at week 16 compared with 38.4% receiving risankizumab.</p>
<div class="lb-trans"><p>主要終點達成，接受 bimekizumab 治療的患者中有 49.1% 在第 16 周達到了 ACR50，而接受 risankizumab 治療的患者中為 38.4%。</p>
</div><p>Improvements were also seen across secondary endpoints, although these did not reach statistical significance within the prespecified testing hierarchy. Numerically higher responses were observed for bimekizumab across all secondary measures.</p>
<div class="lb-trans"><p>在次要終點上也觀察到了改善，儘管這些結果在預先指定的測試層級中未達到統計學顯著性。bimekizumab 在所有次要指標上的反應均高於數值。</p>
</div><p>Professor Iain McInnes, University of Glasgow, said: “Delivering high-level clinical responses is crucial for people with psoriatic arthritis. Achieving ACR50 level responses in clinical trials indicates joint improvements that correlate closely with clinically meaningful reductions in disease activity, inflammation control and consequent improvements in quality of life.</p>
<div class="lb-trans"><p>格拉斯哥大學的 Iain McInnes 教授表示：“提供高水平的臨牀反應對銀屑病關節炎患者至關重要。在臨牀試驗中達到 ACR50 水平的反應表明關節改善，與疾病活動性、炎症控制及隨之而來的生活質量改善密切相關。</p>
</div><p>“The new BE BOLD data, showing bimekizumab achieved superiority vs risankizumab in ACR50 at Week 16 in a direct head-to-head trial design, can support clinicians in making early informed decisions for treating this chronic inflammatory disease.”</p>
<div class="lb-trans"><p>“新的 BE BOLD 數據顯示，bimekizumab 在直接頭對頭試驗設計中在第 16 周的 ACR50 上優於 risankizumab，可以支持臨牀醫生在治療這種慢性炎症性疾病時做出早期知情決策。”</p>
</div><p>Emmanuel Caeymaex, Executive Vice President at UCB, said: “We are proud to announce results demonstrating the superiority of bimekizumab over risankizumab in improving joint outcomes, providing significant evidence that can inform the treatment landscape for psoriatic arthritis.</p>
<div class="lb-trans"><p>UCB 的執行副總裁 Emmanuel Caeymaex 表示：“我們很自豪地宣佈結果，證明 bimekizumab 在改善關節結果方面優於 risankizumab，提供了重要證據，可以為銀屑病關節炎的治療格局提供指導。</p>
</div><p>“Head-to-head trials are the most rigorous approach to comparative clinical research. BE BOLD reflects UCB’s commitment to scientific excellence through generating high-quality evidence, that supports advancing care for people living with psoriatic disease.”</p>
<div class="lb-trans"><p>“頭對頭試驗是比較臨牀研究中最嚴格的方法。BE BOLD 反映了 UCB 對科學卓越的承諾，通過生成高質量的證據，支持改善銀屑病患者的護理。”</p>
</div><p>Early joint improvements were seen as soon as week 4, with 19.9% of patients on bimekizumab achieving ACR50 compared with 7.2% on risankizumab. Complete skin clearance (PASI100) at week 16 was achieved by 53.4% of those receiving bimekizumab and 46.6% receiving risankizumab.</p>
<div class="lb-trans"><p>早期的關節改善在第 4 周就已顯現，接受 bimekizumab 治療的患者中有 19.9% 達到了 ACR50，而接受 risankizumab 治療的患者中為 7.2%。在第 16 周，接受 bimekizumab 的患者中有 53.4% 實現了完全皮膚清除（PASI100），而接受 risankizumab 的患者中為 46.6%。</p>
</div><p>No new safety signals were identified. Candida infections were more frequent with bimekizumab but were mild or moderate, and no cases led to discontinuation. Rates of treatment‑emergent adverse events were comparable between treatment arms, with low and identical discontinuation rates.</p>
<div class="lb-trans"><p>未發現新的安全信號。bimekizumab 的念珠菌感染髮生率較高，但均為輕度或中度，且沒有病例導致停藥。治療出現的不良事件發生率在治療組之間相當，停藥率低且相同。</p>
</div>

UCB 報告 bimekizumab 在銀屑病關節炎治療中取得了積極成果